{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:18:17Z","timestamp":1786979897696,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T00:00:00Z","timestamp":1568419200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,9,14]],"date-time":"2019-09-14T00:00:00Z","timestamp":1568419200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004484","name":"Tehran University of Medical Sciences","doi-asserted-by":"crossref","award":["38435-37-02-97"],"award-info":[{"award-number":["38435-37-02-97"]}],"id":[{"id":"10.13039\/501100004484","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s00262-019-02392-y","type":"journal-article","created":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T22:03:31Z","timestamp":1568412211000},"page":"1597-1603","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["ANTXR1 (TEM8) overexpression in gastric adenocarcinoma makes the protein a potential target of immunotherapy"],"prefix":"10.1007","volume":"68","author":[{"given":"Masoud","family":"Sotoudeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramin","family":"Shakeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanford M.","family":"Dawsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahareh","family":"Sharififard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naser","family":"Ahmadbeigi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4271-8910","authenticated-orcid":false,"given":"Mahmood","family":"Naderi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,9,14]]},"reference":[{"issue":"6","key":"2392_CR1","first-page":"394","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA 68(6):394\u2013424","journal-title":"CA"},{"issue":"8","key":"2392_CR2","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3748\/wjg.14.1149","volume":"14","author":"G Maconi","year":"2008","unstructured":"Maconi G, Manes G, Porro GB (2008) Role of symptoms in diagnosis and outcome of gastric cancer. World J Gastroenterol 14(8):1149\u20131155","journal-title":"World J Gastroenterol"},{"key":"2392_CR3","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.hoc.2017.01.004","volume":"31","author":"S-E Al-Batran","year":"2017","unstructured":"Al-Batran S-E, Lorenzen S (2017) Management of locally advanced gastroesophageal cancer: still a multidisciplinary global challenge? Hematol Oncol Clin 31:441\u2013452","journal-title":"Hematol Oncol Clin"},{"key":"2392_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/cam4.1274","volume":"7","author":"N Charalampakis","year":"2018","unstructured":"Charalampakis N, Economopoulou P, Kotsantis I, Tolia M, Schizas D, Liakakos T, Elimova E, Ajani JA, Psyrri A (2018) Medical management of gastric cancer: a 2017 update. Cancer Med 7:123\u2013133","journal-title":"Cancer Med"},{"key":"2392_CR5","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"Y-J Bang","year":"2010","unstructured":"Bang Y-J, Van Cutsem E, Feyereislova A et al (2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376:687\u2013697","journal-title":"Lancet"},{"key":"2392_CR6","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","volume":"383","author":"CS Fuchs","year":"2014","unstructured":"Fuchs CS, Tomasek J, Yong CJ et al (2014) Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383:31\u201339","journal-title":"Lancet"},{"key":"2392_CR7","doi-asserted-by":"publisher","first-page":"e180013-e","DOI":"10.1001\/jamaoncol.2018.0013","volume":"4","author":"CS Fuchs","year":"2018","unstructured":"Fuchs CS, Doi T, Jang RW et al (2018) Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol 4:e180013-e","journal-title":"JAMA Oncol"},{"key":"2392_CR8","unstructured":"National Comprehensive Cancer Network (2018) NCCN clinical practice guidelines in oncology, gastric cancer, (Version 2.2018). \n                    https:\/\/www.nccn.org\/professionals\/physician_gls\/default.aspx#gastric\n                    \n                  . Accessed 22 May 2018"},{"key":"2392_CR9","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1016\/j.cell.2017.01.017","volume":"168","author":"P Sharma","year":"2017","unstructured":"Sharma P, Hu-Lieskovan S, Wargo JA, Ribas A (2017) Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168:707\u2013723","journal-title":"Cell"},{"key":"2392_CR10","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.2217\/pgs-2018-0077","volume":"19","author":"A Raimondi","year":"2018","unstructured":"Raimondi A, Nichetti F, Peverelli G, Bartolomeo MD, Braud FD, Pietrantonio F (2018) Genomic markers of resistance to targeted treatments in gastric cancer: potential new treatment strategies. Pharmacogenomics 19:1047\u20131068","journal-title":"Pharmacogenomics"},{"key":"2392_CR11","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1126\/science.289.5482.1197","volume":"289","author":"BS Croix","year":"2000","unstructured":"Croix BS, Rago C, Velculescu V et al (2000) Genes expressed in human tumor endothelium. Science 289:1197\u20131202","journal-title":"Science"},{"key":"2392_CR12","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1158\/0008-5472.CAN-03-2408","volume":"64","author":"A Nanda","year":"2004","unstructured":"Nanda A, Carson-Walter EB, Seaman S, Barber TD, Stampfl J, Singh S, Vogelstein B, Kinzler KW, Croix BSJCR (2004) TEM8 interacts with the cleaved C5 domain of collagen \u03b13 (VI). Can Res 64:817\u2013820","journal-title":"Can Res"},{"issue":"7","key":"2392_CR13","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1172\/JCI120481","volume":"128","author":"C Szot","year":"2018","unstructured":"Szot C, Saha S, Zhang XM et al (2018) Tumor stroma\u2013targeted antibody-drug conjugate triggers localized anticancer drug release. J Clin Investig 128(7):2927\u20132943","journal-title":"J Clin Investig"},{"key":"2392_CR14","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1158\/0008-5472.CAN-16-1911","volume":"78","author":"TT Byrd","year":"2018","unstructured":"Byrd TT, Fousek K, Pignata A et al (2018) TEM8\/ANTXR1-specific CAR T cells as a targeted therapy for triple-negative breast cancer. Can Res 78:489\u2013500","journal-title":"Can Res"},{"issue":"4","key":"2392_CR15","doi-asserted-by":"publisher","first-page":"5010","DOI":"10.1002\/jcb.27776","volume":"120","author":"M Sotoudeh","year":"2018","unstructured":"Sotoudeh M, Shirvani SI, Merat S, Ahmadbeigi N, Naderi M (2018) MSLN (Mesothelin), ANTXR1 (TEM8), and MUC3A are the potent antigenic targets for CAR T cell therapy of gastric adenocarcinoma. J Cell Biochem 120(4):5010\u20135017","journal-title":"J Cell Biochem"},{"key":"2392_CR16","unstructured":"Abcam IHC-PARAFFIN PROTOCOL (IHC-P). \n                    https:\/\/www.abcam.com\/ps\/pdf\/protocols\/ihc_p.pdf\n                    \n                  . Accessed 13 Nov 2017"},{"issue":"1","key":"2392_CR17","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/nm.4015","volume":"22","author":"CA Klebanoff","year":"2016","unstructured":"Klebanoff CA, Rosenberg SA, Restifo NP (2016) Prospects for gene-engineered T cell immunotherapy for solid cancers. Nat Med 22(1):26","journal-title":"Nat Med"},{"key":"2392_CR18","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.ccr.2012.01.004","volume":"21","author":"A Chaudhary","year":"2012","unstructured":"Chaudhary A, Hilton MB, Seaman S et al (2012) TEM8\/ANTXR1 blockade inhibits pathological angiogenesis and potentiates tumoricidal responses against multiple cancer types. Cancer Cell 21:212\u2013226","journal-title":"Cancer Cell"},{"key":"2392_CR19","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2016-2312","author":"T Byrd","year":"2016","unstructured":"Byrd T, Fousek K, Pignata A et al (2016) TEM8\/ANTXR1 specific T cells co-target tumor stem cells and tumor vasculature in triple-negative breast cancer. Cancer Res. \n                    https:\/\/doi.org\/10.1158\/1538-7445.AM2016-2312","journal-title":"Cancer Res"},{"issue":"7","key":"2392_CR20","doi-asserted-by":"publisher","first-page":"2927","DOI":"10.1172\/JCI120481","volume":"128","author":"C Szot","year":"2018","unstructured":"Szot C, Saha S, Zhang XM et al (2018) Tumor stroma\u2013targeted antibody-drug conjugate triggers localized anticancer drug release. J Clin Invest 128(7):2927\u20132943","journal-title":"J Clin Invest"},{"key":"2392_CR21","first-page":"3417","volume":"31","author":"LG Gutwein","year":"2011","unstructured":"Gutwein LG, Al-Quran SZ, Fernando S, Fletcher BS, Copeland EM, Grobmyer SR (2011) Tumor endothelial marker 8 expression in triple-negative breast cancer. Anticancer Res 31:3417\u20133422","journal-title":"Anticancer Res"},{"key":"2392_CR22","first-page":"6649","volume":"61","author":"EB Carson-Walter","year":"2001","unstructured":"Carson-Walter EB, Watkins DN, Nanda A, Vogelstein B, Kinzler KW, Croix BS (2001) Cell surface tumor endothelial markers are conserved in mice and humans. Cancer Res 61:6649\u20136655","journal-title":"Cancer Res"},{"issue":"5","key":"2392_CR23","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1016\/j.immuni.2016.10.015","volume":"45","author":"AD Posey Jr","year":"2016","unstructured":"Posey AD Jr, Clausen H, June CHJI (2016) Distinguishing truncated and normal MUC1 glycoform targeting from Tn-MUC1-specific CAR T cells: specificity is the key to safety. Immunity 45(5):947\u2013948","journal-title":"Immunity"},{"key":"2392_CR24","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke H, Muro K, Van Cutsem E et al (2014) Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 15:1224\u20131235","journal-title":"Lancet Oncol"},{"issue":"6","key":"2392_CR25","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/nrc2152","volume":"7","author":"HM Verheul","year":"2007","unstructured":"Verheul HM, Pinedo HMJNRC (2007) Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 7(6):475","journal-title":"Nat Rev Cancer"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-019-02392-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-019-02392-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-019-02392-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T19:09:57Z","timestamp":1599937797000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-019-02392-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,14]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["2392"],"URL":"https:\/\/doi.org\/10.1007\/s00262-019-02392-y","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,14]]},"assertion":[{"value":"12 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed after the approval of Institutional Review Board of Tehran University of Medical Sciences (approval ID: IR.TUMS.DDRI.REC.1397.007).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all patients at the time of surgery for the use of their paraffin-embedded tissue blocks in research after finalizing their diagnostic procedure.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}